Paired comparison of the analytical performance between the OncomineTM Comprehensive Assay v3 and whole-exome sequencing of ovarian cancer tissue

Joanna Lopacinska-Jørgensen,Lau K. Vestergaard,Lone Schejbel,Claus K. Høgdall,Tim Svenstrup Poulsen,Estrid V. Høgdall
DOI: https://doi.org/10.1007/s11033-024-09715-y
IF: 2.7422
2024-07-19
Molecular Biology Reports
Abstract:Next-generation sequencing (NGS) has been implemented in clinical oncology as a personalized medicine tool to identify targetable genetic alterations and to guide treatment decisions. However, the optimal NGS test strategy and target genes for clinical use are still being discussed. The aim was to compare the performance of the OncomineTM Comprehensive Assay v3 (OCAv3) (targeted gene panel) and whole-exome sequencing (WES) to investigate somatic single and multiple nucleotide variants and small indels in ovarian cancer patients.
biochemistry & molecular biology
What problem does this paper attempt to address?